DA Davidson Has Bullish Forecast for PBH FY2025 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Stock analysts at DA Davidson raised their FY2025 EPS estimates for shares of Prestige Consumer Healthcare in a report issued on Monday, February 10th. DA Davidson analyst L. Weiser now anticipates that the company will post earnings per share of $4.50 for the year, up from their previous estimate of $4.46. DA Davidson has a "Buy" rating and a $104.00 price objective on the stock. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. DA Davidson also issued estimates for Prestige Consumer Healthcare's Q4 2025 earnings at $1.30 EPS.

Other analysts have also recently issued research reports about the company. Canaccord Genuity Group lifted their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Oppenheimer lifted their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a report on Thursday. StockNews.com raised shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Friday, January 24th. Raymond James raised shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. Finally, Sidoti lowered Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target on the stock. in a research note on Monday, December 9th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Prestige Consumer Healthcare has an average rating of "Moderate Buy" and an average price target of $92.60.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock traded up $0.15 during mid-day trading on Tuesday, hitting $85.83. 123,022 shares of the company were exchanged, compared to its average volume of 313,708. Prestige Consumer Healthcare has a 12-month low of $62.35 and a 12-month high of $88.36. The company has a market capitalization of $4.25 billion, a P/E ratio of 20.14, a PEG ratio of 2.43 and a beta of 0.50. The business's 50 day simple moving average is $79.27 and its two-hundred day simple moving average is $75.87. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in PBH. Kestra Investment Management LLC purchased a new position in Prestige Consumer Healthcare in the fourth quarter valued at about $27,000. CIBC Private Wealth Group LLC grew its stake in shares of Prestige Consumer Healthcare by 48.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after buying an additional 152 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in Prestige Consumer Healthcare by 562.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company's stock worth $35,000 after acquiring an additional 433 shares in the last quarter. Headlands Technologies LLC purchased a new position in Prestige Consumer Healthcare in the 4th quarter worth approximately $40,000. Finally, nVerses Capital LLC grew its position in Prestige Consumer Healthcare by 200.0% in the third quarter. nVerses Capital LLC now owns 600 shares of the company's stock valued at $43,000 after acquiring an additional 400 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares of the company's stock, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is owned by company insiders.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.